» Articles » PMID: 32947607

The Association Between Transition from Metabolically Healthy Obesity to Metabolic Syndrome, and Incidence of Cardiovascular Disease: Tehran Lipid and Glucose Study

Overview
Journal PLoS One
Date 2020 Sep 18
PMID 32947607
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Considering that the data available on the cardiovascular (CV) risk of metabolically healthy obesity phenotype, and the effect of transition to an unhealthy status are inconsistent, the aim of this study was to investigate the possible role of transition to unhealthy status among metabolically healthy overweight/obese (MHO) subjects on CVD incidence over a median follow-up of 15.9 years. In this large population-based cohort, 6758 participants (41.6% men) aged ≥ 20 years, were enrolled. Participants were divided into 4 groups based on their obesity phenotypes and follow-up results, including persistent metabolically healthy normal weight (MHNW), persistent MHO, transitional MHO and metabolically unhealthy overweight/obese (MUO). Metabolic health was defined as not having metabolic syndrome based on the Joint Interim Statement (JIS) criteria. Multivariable adjusted hazard ratios (HRs) were calculated for cardiovascular events. During follow-up, rate of CVD Incidence per 1000 person-years were 12 and 7 in males and females, respectively. Multivariable adjusted HRs (CI 95%) of CVD incidence among males and females were 1.37 (.78-2.41) and .85 (.34-2.15) in persistent MHO group, 1.55 (1.02-2.37) and .93 (.41-2.12) in transitional MHO group and 2.64 (1.89-3.70) and 2.65 (1.24-5.68) in MUO group. Our findings showed that CVD risk did not increase in the persistent MHO phenotype over a 15.9-year follow-up in both sexes. However, transition from MHO to MUO status during follow-up increased the CVD risk just in male individuals. Further studies are needed to provide conclusive evidence in favor of benign nature of transitional MHO phenotype in females.

Citing Articles

Evaluation of the effectiveness of the Iran-package of essential non-communicable disease (IraPEN) program in reducing cardiovascular disease risk in pilot areas.

Derakhshan S, Khalili D, Mahdavi A, Hashemi-Nazari S, Kavousi A, Hadavandsiri F BMC Public Health. 2025; 25(1):429.

PMID: 39901219 PMC: 11792335. DOI: 10.1186/s12889-024-21168-3.


The prevalence of metabolically healthy obesity and healthy status and related risk factors among Iranian adults: a cohort-based cross-sectional study.

Bagheri P, Babaei-Sarvestani M J Diabetes Metab Disord. 2025; 24(1):41.

PMID: 39801687 PMC: 11711743. DOI: 10.1007/s40200-024-01555-8.


Irruption of Network Analysis to Explain Dietary, Psychological and Nutritional Patterns and Metabolic Health Status in Metabolically Healthy and Unhealthy Overweight and Obese University Students: Ecuadorian Case.

Aguirre-Quezada M, Aranda-Ramirez M Nutrients. 2024; 16(17).

PMID: 39275240 PMC: 11397439. DOI: 10.3390/nu16172924.


The Relationship of Waist Circumference with the Morbidity of Cardiovascular Diseases and All-Cause Mortality in Metabolically Healthy Individuals: A Population-Based Cohort Study.

Su Y, Sun J, Zhou Y, Sun W Rev Cardiovasc Med. 2024; 25(6):212.

PMID: 39076338 PMC: 11270058. DOI: 10.31083/j.rcm2506212.


Cardiovascular disease among bariatric surgery candidates: coronary artery screening and the impact of metabolic syndrome.

Nie Y, Zong H, Li Z, Wang P, Zhang N, Zhou B Diabetol Metab Syndr. 2024; 16(1):180.

PMID: 39075584 PMC: 11285332. DOI: 10.1186/s13098-024-01425-6.


References
1.
Roberson L, Aneni E, Maziak W, Agatston A, Feldman T, Rouseff M . Beyond BMI: The "Metabolically healthy obese" phenotype & its association with clinical/subclinical cardiovascular disease and all-cause mortality -- a systematic review. BMC Public Health. 2014; 14:14. PMC: 3890499. DOI: 10.1186/1471-2458-14-14. View

2.
Alberti K, Eckel R, Grundy S, Zimmet P, Cleeman J, Donato K . Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation;.... Circulation. 2009; 120(16):1640-5. DOI: 10.1161/CIRCULATIONAHA.109.192644. View

3.
Mosca L, Barrett-Connor E, Wenger N . Sex/gender differences in cardiovascular disease prevention: what a difference a decade makes. Circulation. 2011; 124(19):2145-54. PMC: 3362050. DOI: 10.1161/CIRCULATIONAHA.110.968792. View

4.
Palmer B, Clegg D . The sexual dimorphism of obesity. Mol Cell Endocrinol. 2015; 402:113-9. PMC: 4326001. DOI: 10.1016/j.mce.2014.11.029. View

5.
Hadaegh F, Harati H, Ghanbarian A, Azizi F . Association of total cholesterol versus other serum lipid parameters with the short-term prediction of cardiovascular outcomes: Tehran Lipid and Glucose Study. Eur J Cardiovasc Prev Rehabil. 2006; 13(4):571-7. DOI: 10.1097/01.hjr.0000216552.81882.ca. View